Fortress Biotech announces CAEL-101 strategic partnership with Alexion Pharmaceuticals

This article was originally published here

CAEL-101 is a first-in-class amyloid fibril targeted therapy designed to improve organ function by reducing or eliminating amyloid deposits in patients with AL amyloidosis. AL amyloidosis is a

The post Fortress Biotech announces CAEL-101 strategic partnership with Alexion Pharmaceuticals appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply